| Business Summary | | NaPro
BioTherapeutics,
Inc.
is
a
biopharmaceutical
company
focused
on
the
development,
production
and
licensing
of
complex
natural
product
pharmaceuticals,
as
well
as
on
the
development
and
licensing
of
novel
genetic
technologies
for
applications
in
human
therapeutics
and
diagnostics,
pharmacogenomics
and
agribiotechnology.
The
Company's
lead
product
is
paclitaxel,
a
naturally
occurring
chemotherapeutic
anti-cancer
agent
found
in
certain
species
of
yew,
or
Taxus,
trees.
In
addition
to
its
efforts
with
paclitaxel
and
genetics,
the
Company
is
working
on
several
types
of
compounds
that
have
displayed
activity
as
anti-cancer
agents.
The
Company
is
actively
engaged
in
evaluating
the
in-licensing
or
purchase
of
potential
new
products
and/or
technologies,
whether
or
not
those
products
or
technologies
are
derived
from
natural
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NPRO
is
a
natural
product
pharmaceutical
company,
focused
on
the
development,
manufacture
and
commercialization
of
paclitaxel,
a
naturally-occuring
anti-cancer
agent
found
in
certain
species
of
yew
trees.
For
the
six
months
ended
6/30/01,
revenues
increased
51%
to
$6.1
million.
Net
loss
increased
13%
to
$9.8
million.
Revenues
reflect
increased
product
sales.
Higher
loss
suffered
from
increased
research
and
technology
spending. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Leonard Shaykin, 57 Chairman
and CEO | $465K | Sterling Ainsworth, Ph.D., 61 Vice
Chairman, Pres and CSO | 475K | Gordon Link, Jr., 37 CFO,
VP-Fin. and Pres, NaPro Genomics | 304K | Patricia Pilia, Ph.D., 51 Sec.,
Treasurer, Exec. VP | 371K | David Denny, 48 VP,
Operations | 279K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|